Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome

Mendy Ter Avest; Caroline Duineveld; Romy N. Bouwmeester; Laura M. Baas; Lambertus P.W.J. Van Den Heuvel; Saskia M.C. Langemeijer; Jack F.M. Wetzels; Nicole C.A.J. Van De Kar; Rob Ter Heine; R. De Wildt; W. Altena; K. Wijnsma; L. Ter Steeg; A. D. Van Zuilen; M. Eijgelsheim; F. J. Bemelman; D. Severs; E. Bredewold; S. Timmermans; P. Van Paassen; J. F.M. Wetzels; W. A.G. Van Der Meijden; A. E. Van De Logt; J. A.E. Van Wijk; A. H.M. Bouts; E. M. Dorresteijn; V. Gracchi; F. A.P.T. Engels; M. G. Keijzer-Veen; R. W.G. Van Rooij; CUREiHUS study group

doi:10.1093/ndt/gfae244

Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome

Mendy Ter Avest^*, Caroline Duineveld, Romy N. Bouwmeester, Laura M. Baas, Lambertus P.W.J. Van Den Heuvel, Saskia M.C. Langemeijer, Jack F.M. Wetzels, Nicole C.A.J. Van De Kar, Rob Ter Heine, R. De Wildt, W. Altena, K. Wijnsma, L. Ter Steeg, A. D. Van Zuilen, M. Eijgelsheim, F. J. Bemelman, D. Severs, E. Bredewold, S. Timmermans, P. Van PaassenJ. F.M. Wetzels, W. A.G. Van Der Meijden, A. E. Van De Logt, J. A.E. Van Wijk, A. H.M. Bouts, E. M. Dorresteijn, V. Gracchi, F. A.P.T. Engels, M. G. Keijzer-Veen, R. W.G. Van Rooij, CUREiHUS study group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	598-601
Number of pages	4
Journal	Nephrology Dialysis Transplantation
Volume	40
Issue number	3
DOIs	https://doi.org/10.1093/ndt/gfae244
Publication status	Published - 1 Mar 2025

Access to Document

10.1093/ndt/gfae244Licence: CC BY-NC

Cite this

Ter Avest, M., Duineveld, C., Bouwmeester, R. N., Baas, L. M., Van Den Heuvel, L. P. W. J., Langemeijer, S. M. C., Wetzels, J. F. M., Van De Kar, N. C. A. J., Ter Heine, R., De Wildt, R., Altena, W., Wijnsma, K., Ter Steeg, L., Van Zuilen, A. D., Eijgelsheim, M., Bemelman, F. J., Severs, D., Bredewold, E., Timmermans, S., ... CUREiHUS study group (2025). Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome. Nephrology Dialysis Transplantation, 40(3), 598-601. https://doi.org/10.1093/ndt/gfae244

@article{f39842985b00433d96555e5e79cec013,

title = "Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome",

author = "{Ter Avest}, Mendy and Caroline Duineveld and Bouwmeester, {Romy N.} and Baas, {Laura M.} and {Van Den Heuvel}, {Lambertus P.W.J.} and Langemeijer, {Saskia M.C.} and Wetzels, {Jack F.M.} and {Van De Kar}, {Nicole C.A.J.} and {Ter Heine}, Rob and {De Wildt}, R. and W. Altena and K. Wijnsma and {Ter Steeg}, L. and {Van Zuilen}, {A. D.} and M. Eijgelsheim and Bemelman, {F. J.} and D. Severs and E. Bredewold and S. Timmermans and {Van Paassen}, P. and Wetzels, {J. F.M.} and {Van Der Meijden}, {W. A.G.} and {Van De Logt}, {A. E.} and {Van Wijk}, {J. A.E.} and Bouts, {A. H.M.} and Dorresteijn, {E. M.} and V. Gracchi and Engels, {F. A.P.T.} and Keijzer-Veen, {M. G.} and {Van Rooij}, {R. W.G.} and {CUREiHUS study group}",

note = "Funding Information: This work was supported by grants from Zorgverzekeraars Nederland and ZonMw, \u201CGoed Gebruik Geneesmiddelen\u201D (project number 836031008). They did not have any role in data collection, analysis, or submission of this manuscript. Funding Information: N.v.d.K., J.W., and B.v.d.H. are members of the European Reference Network for Rare Kidney Diseases (ERKNet)-Project No 739532. J.W. received grants from Alexion, HiBio, Novartis, and consultancy fees from Novartis, HiBio, and Otsuka. N.v.d.K. received consultancy fees from Roche Pharmaceuticals, Alexion, and Novartis and is sub-investigator in the APL2-C3G trial, Apellis. R.t.H. has received research funding from AMGEN. The other authors declare that they have no conflict of interest. Funding Information: Thanks to the CUREiHUS study group for its participation in this study; a complete membership list appears in \{"}Appendix\{"}. This work was supported by grants from Zorgverzekeraars Ned-erland and ZonMw, \{"}Goed Gebruik Geneesmiddelen\{"}(project number 836031008). They did not have any role in data collection, analysis, or submission of this manuscript.",

year = "2025",

month = mar,

day = "1",

doi = "10.1093/ndt/gfae244",

language = "English",

volume = "40",

pages = "598--601",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "3",

}

Ter Avest, M, Duineveld, C, Bouwmeester, RN, Baas, LM, Van Den Heuvel, LPWJ, Langemeijer, SMC, Wetzels, JFM, Van De Kar, NCAJ, Ter Heine, R, De Wildt, R, Altena, W, Wijnsma, K, Ter Steeg, L, Van Zuilen, AD, Eijgelsheim, M, Bemelman, FJ, Severs, D, Bredewold, E, Timmermans, S , Van Paassen, P, Wetzels, JFM, Van Der Meijden, WAG, Van De Logt, AE, Van Wijk, JAE, Bouts, AHM, Dorresteijn, EM, Gracchi, V, Engels, FAPT, Keijzer-Veen, MG, Van Rooij, RWG & CUREiHUS study group 2025, 'Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome', Nephrology Dialysis Transplantation, vol. 40, no. 3, pp. 598-601. https://doi.org/10.1093/ndt/gfae244

TY - JOUR

T1 - Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome

AU - Ter Avest, Mendy

AU - Duineveld, Caroline

AU - Bouwmeester, Romy N.

AU - Baas, Laura M.

AU - Van Den Heuvel, Lambertus P.W.J.

AU - Langemeijer, Saskia M.C.

AU - Wetzels, Jack F.M.

AU - Van De Kar, Nicole C.A.J.

AU - Ter Heine, Rob

AU - De Wildt, R.

AU - Altena, W.

AU - Wijnsma, K.

AU - Ter Steeg, L.

AU - Van Zuilen, A. D.

AU - Eijgelsheim, M.

AU - Bemelman, F. J.

AU - Severs, D.

AU - Bredewold, E.

AU - Timmermans, S.

AU - Van Paassen, P.

AU - Wetzels, J. F.M.

AU - Van Der Meijden, W. A.G.

AU - Van De Logt, A. E.

AU - Van Wijk, J. A.E.

AU - Bouts, A. H.M.

AU - Dorresteijn, E. M.

AU - Gracchi, V.

AU - Engels, F. A.P.T.

AU - Keijzer-Veen, M. G.

AU - Van Rooij, R. W.G.

AU - CUREiHUS study group

N1 - Funding Information: This work was supported by grants from Zorgverzekeraars Nederland and ZonMw, \u201CGoed Gebruik Geneesmiddelen\u201D (project number 836031008). They did not have any role in data collection, analysis, or submission of this manuscript. Funding Information: N.v.d.K., J.W., and B.v.d.H. are members of the European Reference Network for Rare Kidney Diseases (ERKNet)-Project No 739532. J.W. received grants from Alexion, HiBio, Novartis, and consultancy fees from Novartis, HiBio, and Otsuka. N.v.d.K. received consultancy fees from Roche Pharmaceuticals, Alexion, and Novartis and is sub-investigator in the APL2-C3G trial, Apellis. R.t.H. has received research funding from AMGEN. The other authors declare that they have no conflict of interest. Funding Information: Thanks to the CUREiHUS study group for its participation in this study; a complete membership list appears in \"Appendix\". This work was supported by grants from Zorgverzekeraars Ned-erland and ZonMw, \"Goed Gebruik Geneesmiddelen\"(project number 836031008). They did not have any role in data collection, analysis, or submission of this manuscript.

PY - 2025/3/1

Y1 - 2025/3/1

U2 - 10.1093/ndt/gfae244

DO - 10.1093/ndt/gfae244

M3 - Article

SN - 0931-0509

VL - 40

SP - 598

EP - 601

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 3

ER -